Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Iterum Therapeutics plcITRM · Entity 72802 | Director | May 24, 2019 | May 29, 2019 |
| LUMOS PHARMA, INC.(NLNK) · Entity 85102 | Director | May 12, 2017 | May 16, 2017 |
| Milestone Pharmaceuticals Inc.MIST · Entity 6561 | Director | June 05, 2020 | June 08, 2020 |
| Neos Therapeutics, Inc.NEOS · Entity 141061 | Director | July 03, 2017 | July 05, 2017 |
| PDL BIOPHARMA, INC.PDLI · Entity 143144 | Director | June 08, 2018 | June 12, 2018 |
| Vistagen Therapeutics, Inc.VTGN · Entity 7955 | Director | October 27, 2025 | November 04, 2025 |
| XERIS PHARMACEUTICALS INCXERS · Entity 134906 | Director · Chief Executive Officer | October 05, 2021 | October 05, 2021 |
| Xeris Biopharma Holdings, Inc.XERS · Entity 4670 | Director · See Remarks | January 31, 2024 | January 31, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Iterum Therapeutics plc
Report date May 24, 2019 · Filed May 29, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 31,390 |
Reported balance
After 2019-05-24 transaction · row 1
1 source rowRow 1 · 2019-05-24 · Exercise / conversion · Acquired 6,154 · Balance 31,390 F1: Restricted stock units converted into ordinary shares on a one-for-one basis upon vesting of the units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-05-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-05-24 · Exercise / conversion · Disposed 6,154 · Balance 0 F1: Restricted stock units converted into ordinary shares on a one-for-one basis upon vesting of the units. F2: On May 24, 2018, the reporting person was granted an award of 6,154 restricted stock units, which vested on May 24, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units converted into ordinary shares on a one-for-one basis upon vesting of the units.
F2: On May 24, 2018, the reporting person was granted an award of 6,154 restricted stock units, which vested on May 24, 2019.
LUMOS PHARMA, INC.
Report date May 12, 2017 · Filed May 16, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.42 · Expires 2027-05-11 | Direct | 13,309 |
Reported balance
After 2017-05-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-05-12 · Grant · Acquired 13,309 · Balance 13,309 F1: Automatic grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2009 Equity Incentive Plan (the "Plan"). One hundred percent (100%) of the shares shall vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the first Annual Meeting following the date of grant, in each case subject to the Reporting Person's continuous service as of such date. The option expires ten years after the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Automatic grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2009 Equity Incentive Plan (the "Plan"). One hundred percent (100%) of the shares shall vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the first Annual Meeting following the date of grant, in each case subject to the Reporting Person's continuous service as of such date. The option expires ten years after the date of grant.
Milestone Pharmaceuticals Inc.
Report date June 05, 2020 · Filed June 08, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.74 · Expires 2030-06-05 | Direct | 15,000 |
Reported balance
After 2020-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-05 · Grant · Acquired 15,000 · Balance 15,000 F1: The shares subject to this option shall vest in equal monthly installments over the 12 months commencing July 5, 2020, provided that the shares subject to this option shall vest in full on the date of Issuer's 2021 annual meeting of shareholders, subject to recipient continuing to provide service to the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest in equal monthly installments over the 12 months commencing July 5, 2020, provided that the shares subject to this option shall vest in full on the date of Issuer's 2021 annual meeting of shareholders, subject to recipient continuing to provide service to the Issuer through such vesting date.
Neos Therapeutics, Inc.
Report date July 03, 2017 · Filed July 05, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.65 · Expires 2027-07-03 | Direct | 18,322 |
Reported balance
After 2017-07-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-07-03 · Grant · Acquired 18,322 · Balance 18,322 F1: This stock option vests in equal quarterly installments over a one-year period which begins on June 15, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option vests in equal quarterly installments over a one-year period which begins on June 15, 2017.
PDL BIOPHARMA, INC.
Report date June 08, 2018 · Filed June 12, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 214,563 |
Reported balance
After 2018-06-08 transaction · row 1
1 source rowRow 1 · 2018-06-08 · Grant · Acquired 54,348 · Balance 214,563 F1: The grant will cliff-vest on the first anniversary of the date of grant so long as the grant recipient continues to serve on the Board of Directors of PDL BioPharma, Inc. |
Filing footnotes · ownership attribution and instrument terms
F1: The grant will cliff-vest on the first anniversary of the date of grant so long as the grant recipient continues to serve on the Board of Directors of PDL BioPharma, Inc.
Vistagen Therapeutics, Inc.
Report date October 27, 2025 · Filed November 04, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.90 · Expires 2035-10-27 | Direct | 35,200 |
Reported balance
After 2025-10-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-10-27 · Grant · Acquired 35,200 · Balance 35,200 F1: Represents stock options granted in connection with the reporting person's appointment to the Issuer's Board of Directors. The stock options were granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, and vest in three equal annual installments, beginning on the first anniversary of the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents stock options granted in connection with the reporting person's appointment to the Issuer's Board of Directors. The stock options were granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, and vest in three equal annual installments, beginning on the first anniversary of the date of the grant.
XERIS PHARMACEUTICALS INC
Report date October 05, 2021 · Filed October 05, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 410,833 |
Reported balance
After 2021-10-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-10-05 · Disposition to issuer · Disposed 197,231 · Balance 410,833 F1: On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among the Issuer ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), Xeris Biopharma Holdings, Inc. ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction"). F2: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), all existing shares of Xeris common stock (the "Xeris common stock") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of Xeris common stock received upon vesting of Xeris RSUs (as defined below), net of shares of Xeris common stock withheld for tax. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-10-05 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2021-10-05 · Disposition to issuer · Disposed 410,833 · Balance 0 F3: Represents restricted stock units each representing a contingent right to receive one share of Xeris common stock (the "Xeris RSU"). At the Effective Time, each Xeris RSU that outstanding immediately prior to the Effective Time was automatically converted into a restricted stock unit representing a contingent right to acquire one share of HoldCo common stock (the "HoldCo RSU") on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. Excludes vested Xeris RSUs as of the Effective Time. |
| Common StockSEC Table I · non-derivative | IndirectBy Paul R. Edick 2008 Revocable Trust u/d/t dated 6/25/2018 | 0 |
Reported balance
After 2021-10-05 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2021-10-05 · Disposition to issuer · Disposed 13,430 · Balance 0 F1: On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among the Issuer ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), Xeris Biopharma Holdings, Inc. ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction"). F2: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), all existing shares of Xeris common stock (the "Xeris common stock") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of Xeris common stock received upon vesting of Xeris RSUs (as defined below), net of shares of Xeris common stock withheld for tax. F4: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.55 · Expires 2027-01-27 | Direct | 0 |
Reported balance
After 2021-10-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-10-05 · Disposition to issuer · Disposed 668,065 · Balance 0 F5: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F6: These options are fully vested as of the date hereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.55 · Expires 2027-06-11 | Direct | 0 |
Reported balance
After 2021-10-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-10-05 · Disposition to issuer · Disposed 69,822 · Balance 0 F5: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F6: These options are fully vested as of the date hereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.93 · Expires 2028-01-31 | Direct | 0 |
Reported balance
After 2021-10-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-10-05 · Disposition to issuer · Disposed 98,252 · Balance 0 F5: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F7: 25% of these shares shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. F8: These options are early exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.88 · Expires 2029-01-31 | Direct | 0 |
Reported balance
After 2021-10-05 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-10-05 · Disposition to issuer · Disposed 200,000 · Balance 0 F5: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F7: 25% of these shares shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.08 · Expires 2031-01-31 | Direct | 0 |
Reported balance
After 2021-10-05 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-10-05 · Disposition to issuer · Disposed 400,000 · Balance 0 F5: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F7: 25% of these shares shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among the Issuer ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), Xeris Biopharma Holdings, Inc. ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction").
F2: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), all existing shares of Xeris common stock (the "Xeris common stock") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of Xeris common stock received upon vesting of Xeris RSUs (as defined below), net of shares of Xeris common stock withheld for tax.
F3: Represents restricted stock units each representing a contingent right to receive one share of Xeris common stock (the "Xeris RSU"). At the Effective Time, each Xeris RSU that outstanding immediately prior to the Effective Time was automatically converted into a restricted stock unit representing a contingent right to acquire one share of HoldCo common stock (the "HoldCo RSU") on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. Excludes vested Xeris RSUs as of the Effective Time.
F4: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F5: At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option.
F6: These options are fully vested as of the date hereof.
F7: 25% of these shares shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months.
F8: These options are early exercisable.
Xeris Biopharma Holdings, Inc.
Report date January 31, 2024 · Filed January 31, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,788,064 |
Reported balance
After 2024-01-31 transaction · row 1
1 source rowRow 1 · 2024-01-31 · Grant · Acquired 1,500,000 · Balance 3,788,064 F1: These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years. |
| Stock Appreciation RightSEC Table II · derivative / convertible security · Conversion / exercise price $2.46 · Expires 2026-03-03 | Direct | 500,000 |
Reported balance
After 2024-01-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-01-31 · Grant · Acquired 500,000 · Balance 500,000 F3: The award will vest in full on the two-year anniversary of the grant date. F4: Upon exercise, the Stock Appreciation Right will be settled in cash. |
| Common StockSEC Table I · non-derivative | IndirectBy: Paul R. Edick 2008 Revocable Trust u/d/t dated 6/25/2018 | 33,430 |
Reported balance
Holding disclosure · report date 2024-01-31 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 33,430 F2: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years.
F2: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F3: The award will vest in full on the two-year anniversary of the grant date.
F4: Upon exercise, the Stock Appreciation Right will be settled in cash.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Sucampo Pharmaceuticals, Inc.
Report date February 13, 2018 · Filed February 13, 2018
Section 16 reporting ended · disclosed 2018-02-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, Class ASEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-02-13 transaction · row 1
1 source rowRow 1 · 2018-02-13 · Disposition to issuer · Disposed 14,930 · Balance 0 F1: This common stock was purchased for $18.00 per share share in cash, subject to any required withholding of taxes and without interest, upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to that certain Agreement and Plan of Merger by and among Mallinckrodt plc, Sun Acquisition Co. and Sucampo Pharmaceuticals, Inc. dated December 23, 2017 (the "Merger Agreement"). The common stock consisted of restricted stock units that were accelerated as a result of the Merger Agreement. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.30 · Expires 2027-06-01 | Direct | 0 |
Reported balance
After 2018-02-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-02-13 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: This common stock was purchased for $18.00 per share share in cash, subject to any required withholding of taxes and without interest, upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to that certain Agreement and Plan of Merger by and among Mallinckrodt plc, Sun Acquisition Co. and Sucampo Pharmaceuticals, Inc. dated December 23, 2017 (the "Merger Agreement"). The common stock consisted of restricted stock units that were accelerated as a result of the Merger Agreement.
F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 24, 2018 Filed May 29, 2018 17:26 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | GrantRestricted Stock Units · Derivative | 6,154 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-033908 · doc4.xml · derivative · entry 1 Edick Paul R · CIK 0001531178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,154 Underlying: Ordinary Shares · 6,154 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Ordinary Shares. F2 · derivative.exercise_date: Subject to the Reporting Person providing continuous service, the RSU shall vest on May 24, 2019. F2 · derivative.expiration_date: Subject to the Reporting Person providing continuous service, the RSU shall vest on May 24, 2019. Read SEC document |
| February 13, 2018 Filed Feb 13, 2018 16:54 UTC | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | Disposition to issuerDirector Stock Option (right to buy) · Derivative | 10,000 | $7.70 Strike: $10.30 | $77,000.00 |
DisclosureSEC source: 0001171843-18-001108 · form4.xml · derivative · entry 2 Edick Paul R · CIK 0001531178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2027-06-01 F2 · derivative.exercise_date: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement. Read SEC document |
| February 13, 2018 Filed Feb 13, 2018 16:54 UTC | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | Disposition to issuerCommon Stock, Class A | 14,930 | $18.00 | $268,740.00 |
DisclosureSEC source: 0001171843-18-001108 · form4.xml · nonDerivative · entry 1 Edick Paul R · CIK 0001531178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: This common stock was purchased for $18.00 per share share in cash, subject to any required withholding of taxes and without interest, upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to that certain Agreement and Plan of Merger by and among Mallinckrodt plc, Sun Acquisition Co. and Sucampo Pharmaceuticals, Inc. dated December 23, 2017 (the "Merger Agreement"). The common stock consisted of restricted stock units that were accelerated as a result of the Merger Agreement. Read SEC document |
| July 03, 2017 Filed Jul 5, 2017 17:59 UTC | Neos Therapeutics, Inc. NEOS · Entity 141061 | GrantStock Option (Right to Buy) · Derivative | 18,322 | $0.00 Strike: $7.65 | $0.00 |
DisclosureSEC source: 0001104659-17-043628 · a4.xml · derivative · entry 1 Edick Paul R · CIK 0001531178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,322 Underlying: Common Stock · 18,322 shares Expires 2027-07-03 F1 · derivative.exercise_date: This stock option vests in equal quarterly installments over a one-year period which begins on June 15, 2017. Read SEC document |
| June 09, 2017 Filed Jun 13, 2017 00:19 UTC | PDL BIOPHARMA, INC. PDLI · Entity 143144 | GrantCommon stock | 60,729 | $2.47 | $150,000.63 |
DisclosureSEC source: 0000882104-17-000065 · wf-form4_149731316693886.xml · nonDerivative · entry 1 Edick Paul R · CIK 0001531178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,215 F1 · shares: The grant will cliff-vest on the first anniversary of the date of grant so long as the grant recipient continues to serve on the Board of Directors of PDL BioPharma, Inc. During the one-year vesting period, the grant recipient will have the right to vote the shares and receive any dividends and other distributions paid, except that dividends and other distributions will be accumulated and will vest and be paid, with interest, on the earlier of the same vesting conditions as the original award or March 15th of the year following the payment of such dividend or distribution to all stockholders. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 21:59 UTC | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | GrantDirector Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $10.30 | $0.00 |
DisclosureSEC source: 0001171843-17-003483 · f4_edick060517.xml · derivative · entry 2 Edick Paul R · CIK 0001531178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Class A Common Stock · 10,000 shares Expires 2027-06-01 F2 · derivative.exercise_date: Vesting commences July 1, 2017 in 12-monthly installments. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 21:59 UTC | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | GrantCommon Stock | 5,130 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-17-003483 · f4_edick060517.xml · nonDerivative · entry 1 Edick Paul R · CIK 0001531178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,930 F1 · security: Common stock granted consists of restricted stock units that vest in a single installment on June 1, 2018. Read SEC document |
| June 01, 2017 Filed Jul 7, 2017 16:55 UTC Amendment | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | GrantDirector Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $10.30 | $0.00 |
DisclosureSEC source: 0001171843-17-004005 · formfoura.xml · derivative · entry 2 Edick Paul R · CIK 0001531178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Class A Common Stock · 10,000 shares Expires 2027-06-01 F2 · derivative.exercise_date: Vesting commences July 1, 2017 in 12-monthly installments. Read SEC document |
| June 01, 2017 Filed Jul 7, 2017 16:55 UTC Amendment | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | GrantCommon Stock | 5,130 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-17-004005 · formfoura.xml · nonDerivative · entry 1 Edick Paul R · CIK 0001531178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,830 F1 · security: Common stock granted consists of restricted stock units that vest in a single installment on June 1, 2018. Read SEC document |
| May 12, 2017 Filed May 16, 2017 17:20 UTC | LUMOS PHARMA, INC. (NLNK) · Entity 85102 | GrantStock Option (Right to Buy) · Derivative | 13,309 | $0.00 Strike: $17.42 | $0.00 |
DisclosureSEC source: 0001126234-17-000052 · wf-form4_149496962117427.xml · derivative · entry 1 Edick Paul R · CIK 0001531178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,309 Underlying: Common Stock · 13,309 shares Expires 2027-05-11 F1 · derivative.exercise_date: Automatic grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2009 Equity Incentive Plan (the "Plan"). One hundred percent (100%) of the shares shall vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the first Annual Meeting following the date of grant, in each case subject to the Reporting Person's continuous service as of such date. The option expires ten years after the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.